Skip to main content

Table 3 Overall survival (OS) regarding different treatment regimens

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Treatment

Number of patients

OS months

Range

(Mean ± SD)

Median

VCD

54

1–156

28.5 ± 30.5

20.3

VRD

10

3–63

27.5 ± 17.7

26.4

VTD

8

12–77

41.5 ± 23.2

44.5

Endoxan-Dexa

9

2–20

8.13 ± 6.9

5.1

  1. VCD Velcade® (bortezomib)-cyclophosphamide-dexamethasone, VRD Velcade® (bortezomib)-Revlimid® (lenalidomide)-dexamethasone, VTD Velcade® (bortezomib)-thalidomide-dexamethasone; Endoxan-Dexa endoxan-dexamethasone